, 3 Service de Psychiatrie et de Psychologie Médicale de l'adulte, Centre Expert Dépression Résistante FondaMental, SYLIA-STAT, vol.4, p.92340

F. Bourg-la-reine, Service de Psychiatrie adulte, Centre Expert Dépression Résistante FondaMental, Hôpital Fernand-Widal, issue.5

, Service de Psychiatrie de l'adulte, CS 10217, Centre Expert Dépression Résistante FondaMental

, 11 Pôle de Psychiatrie Générale et Universitaire, Centre Expert Dépression Résistante FondaMental, CH Charles Perrens, UMR INRA 1286, NutriNeuro, Inserm U1253 imaging and Brain : iBrain

C. Murray, T. Vos, R. Lozano, M. Naghavi, A. D. Flaxman et al., Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the global burden of disease study 2010, Lancet, vol.380, issue.9859, pp.2197-223, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00827610

H. Wittchen, Generalized anxiety disorder: prevalence, burden, and cost to society, Depress Anxiety, vol.16, issue.4, pp.162-71, 2002.

W. S. Gilmer, M. H. Trivedi, A. J. Rush, S. R. Wisniewski, J. Luther et al., Factors associated with chronic depressive episodes: a preliminary report from the STAR-D project, Acta Psychiatr Scand, vol.112, issue.6, pp.425-458, 2005.

J. A. Murphy and G. J. Byrne, Prevalence and correlates of the proposed DSM-5 diagnosis of chronic depressive disorder, J Affect Disord, vol.139, issue.2, pp.172-80, 2012.

A. J. Rush, M. H. Trivedi, S. R. Wisniewski, A. A. Nierenberg, J. W. Stewart et al., Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report, Am J Psychiatry, vol.163, issue.11, pp.1905-1922, 2006.

M. H. Trivedi, A. J. Rush, S. R. Wisniewski, A. A. Nierenberg, D. Warden et al., Evaluation of outcomes with citalopram for depression using measurementbased care in STAR*D: implications for clinical practice, Am J Psychiatry, vol.163, issue.1, pp.28-40, 2006.

D. Bennabi, B. Aouizerate, W. El-hage, O. Doumy, F. Moliere et al., Risk factors for treatment resistance in unipolar depression: a systematic review, J Affect Disord, vol.171, pp.137-178, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02173561

D. Souery, P. Oswald, I. Massat, U. Bailer, J. Bollen et al., Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study, J Clin Psychiatry, vol.68, issue.7, pp.1062-70, 2007.

M. Balestri, R. Calati, D. Souery, A. Kautzky, S. Kasper et al., Socio-demographic and clinical predictors of treatment resistant depression: a prospective European multicenter study, J Affect Disord, vol.189, pp.224-256, 2016.

D. Bennabi, A. Yrondi, T. Charpeaud, J. Genty, S. Destouches et al., Clinical guidelines for the management of depression with specific comorbid psychiatric conditions French recommendations from experts (the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental), BMC Psychiatry, vol.19, issue.1, pp.1-9, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02094202

L. Samalin, M. Abbar, P. Courtet, S. Guillaume, S. Lancrenon et al., Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics, Encephale, vol.39, issue.4, pp.189-203, 2013.

P. Llorca, P. Courtet, P. Martin, M. Abbar, C. Gay et al., Screening and management of bipolar disorders: methodology, Encephale, vol.36, issue.4, pp.79-85, 2010.

G. S. Malhi, R. Hitching, M. Berk, P. Boyce, R. Porter et al., Pharmacological management of unipolar depression, Acta Psychiatr Scand Suppl, vol.443, pp.6-23, 2013.

S. H. Kennedy, R. W. Lam, R. S. Mcintyre, S. V. Tourjman, V. Bhat et al., Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the Management of Adults with major depressive disorder: section 3. Pharmacological Treatments Can J Psychiatry, vol.61, pp.540-60, 2016.

A. Cleare, C. M. Pariante, A. H. Young, I. M. Anderson, D. Christmas et al., Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines, J Psychopharmacol (Oxford), vol.29, issue.5, pp.459-525, 2015.

M. Bauer, A. Pfennig, E. Severus, P. C. Whybrow, J. Angst et al., World Federation of Societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders, World J Biol Psychiatry, vol.14, issue.5, pp.334-85, 2013.

. Gelenberg, Practice guideline for the treatment of patients with major depressive disorder, 2010.

, Depression in adults: recognition and management | Guidance and guidelines | NICE, 2017.

M. Adli, C. Baethge, A. Heinz, N. Langlitz, and M. Bauer, Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review, Eur Arch Psychiatry Clin Neurosci, vol.255, issue.6, pp.387-400, 2005.

C. Hiemke, P. Baumann, N. Bergemann, A. Conca, O. Dietmaier et al., AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update, Pharmacopsychiatry, vol.44, issue.6, pp.195-235, 2011.

J. D. Amsterdam and N. J. Berwish, High dose tranylcypromine therapy for refractory depression, Pharmacopsychiatry, vol.22, issue.1, pp.21-26, 1989.

B. E. Dornseif, S. R. Dunlop, J. H. Potvin, and J. F. Wernicke, Effect of dose escalation after low-dose fluoxetine therapy, Psychopharmacol Bull, vol.25, issue.1, pp.71-80, 1989.

O. Benkert, A. Szegedi, H. Wetzel, H. J. Staab, W. Meister et al., Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment response, Acta Psychiatr Scand, vol.95, issue.4, pp.288-96, 1997.

E. Schweizer, M. Rynn, L. A. Mandos, N. Demartinis, F. García-españa et al., The antidepressant effect of sertraline is not enhanced by dose titration: results from an outpatient clinical trial, Int Clin Psychopharmacol, vol.16, issue.3, pp.137-180, 2001.

F. Hieronymus, J. F. Emilsson, S. Nilsson, and E. Eriksson, Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression, Mol Psychiatry, vol.21, issue.4, pp.523-553, 2016.

E. Jakubovski, A. L. Varigonda, N. Freemantle, M. J. Taylor, and M. H. Bloch, Systematic review and meta-analysis: dose-response relationship of selective serotonin reuptake inhibitors in major depressive disorder, Am J Psychiatry, vol.173, issue.2, pp.174-83, 2016.

G. I. Papakostas, M. Fava, and M. E. Thase, Treatment of SSRI-resistant depression: a meta-analysis comparing within-versus across-class switches, Biol Psychiatry, vol.63, issue.7, pp.699-704, 2008.

D. Souery, A. Serretti, R. Calati, P. Oswald, I. Massat et al., Switching antidepressant class does not improve response or remission in treatment-resistant depression, J Clin Psychopharmacol, vol.31, issue.4, pp.512-518, 2011.

M. Dold, A. Kautzky, L. Bartova, U. Rabl, D. Souery et al., Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers -a pharmacoepidemiological cross-sectional multicenter study, Eur Neuropsychopharmacol, vol.26, issue.12, pp.1960-71, 2016.

J. E. Rojo, R. S. Agüera, L. De-la-gándara, J. De-pedro, and J. M. , Combined antidepressants: clinical experience, Acta Psychiatr Scand Suppl, vol.428, pp.25-31, 2005.

P. Blier, G. Gobbi, J. E. Turcotte, C. De-montigny, N. Boucher et al., Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation, Eur Neuropsychopharmacol, vol.19, issue.7, pp.457-65, 2009.

N. A. Crossley and M. Bauer, Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials, J Clin Psychiatry, vol.68, issue.6, pp.935-975, 2007.

J. C. Nelson, P. Baumann, K. Delucchi, R. Joffe, and C. Katona, A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression, J Affect Disord, vol.168, pp.269-75, 2014.

J. C. Nelson and G. I. Papakostas, Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials, Am J Psychiatry, vol.166, issue.9, pp.980-91, 2009.

P. Turner, R. Kantaria, and A. H. Young, A systematic review and meta-analysis of the evidence base for add-on treatment for patients with major depressive disorder who have not responded to antidepressant treatment: a European perspective, J Psychopharmacol (Oxford), vol.28, issue.2, pp.85-98, 2014.

M. Härter, C. Klesse, I. Bermejo, F. Schneider, and M. Berger, Unipolar depression: diagnostic and therapeutic recommendations from the current S3/National Clinical Practice Guideline, Dtsch Arztebl Int, vol.107, issue.40, pp.700-708, 2010.

J. Dorée, J. D. Rosiers, V. Lew, A. Gendron, R. Elie et al., Quetiapine augmentation of treatment-resistant depression: a comparison with lithium, Curr Med Res Opin, vol.23, issue.2, pp.333-374, 2007.

X. Zhou, A. V. Ravindran, B. Qin, D. Giovane, C. Li et al., Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network metaanalysis, J Clin Psychiatry, vol.76, issue.4, pp.487-98, 2015.

G. I. Keitner, S. J. Garlow, C. E. Ryan, P. T. Ninan, D. A. Solomon et al., A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression, J Psychiatr Res, vol.43, issue.3, pp.205-219, 2009.

R. A. Mahmoud, G. J. Pandina, I. Turkoz, C. Kosik-gonzalez, C. M. Canuso et al., Risperidone for treatment-refractory major depressive disorder: a randomized trial, Ann Intern Med, vol.147, issue.9, pp.593-602, 2007.

X. Zhou, G. I. Keitner, B. Qin, A. V. Ravindran, M. Bauer et al., Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis, Int J Neuropsychopharmacol, vol.18, issue.11, 2015.

A. A. Nierenberg, M. Fava, M. H. Trivedi, S. R. Wisniewski, M. E. Thase et al., A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report, Am J Psychiatry, vol.163, issue.9, 2006.

R. L. Gutierrez, R. Mckercher, J. Galea, and K. L. Jamison, Lamotrigine augmentation strategy for patients with treatment-resistant depression, CNS Spectrums, vol.10, issue.10, pp.800-805, 2005.

J. G. Barbee, T. R. Thompson, N. J. Jamhour, J. W. Stewart, E. J. Conrad et al., A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatmentrefractory unipolar depression, J Clin Psychiatry, vol.72, issue.10, pp.1405-1417, 2011.

S. V. Parikh, L. C. Quilty, P. Ravitz, M. Rosenbluth, B. Pavlova et al., Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the Management of Adults with major depressive disorder: section 2. Psychological Treatments Can J Psychiatry, vol.61, pp.524-563, 2016.

S. Van-bronswijk, N. Moopen, L. Beijers, H. G. Ruhe, and F. Peeters, Effectiveness of psychotherapy for treatment-resistant depression: a meta-analysis and meta-regression, Psychol Med, vol.49, issue.3, pp.366-79, 2019.

A. J. Rush, H. C. Kraemer, H. A. Sackeim, M. Fava, M. H. Trivedi et al., Report by the ACNP task force on response and remission in major depressive disorder, Neuropsychopharmacology, vol.31, issue.9, pp.1841-53, 2006.

, Publisher's Note

, Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations